Study of ENMD-2076 in Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess the safety, tolerability, maximum tolerated dose, and
clinical benefit of treatment with ENMD-2076 administered orally once daily over a range of
doses in patients with relapsed or refractory multiple myeloma.